← FDA DRUG APPROVALS

FDA ANDA · ANDA062222

OXACILLIN SODIUM

Sponsor: ANI PHARMS

APPLICATION
ANDA062222
TYPE
ANDA
ORIGINAL APPROVAL
1980-03-10
LATEST ACTION
2000-07-07
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

OXACILLIN SODIUMDiscontinued
OXACILLIN SODIUM EQ 500MG BASE · CAPSULE · ORAL
OXACILLIN SODIUMDiscontinued
OXACILLIN SODIUM EQ 250MG BASE · CAPSULE · ORAL

Approval history

2000-07-07Manufacturing (CMC) · Supplement 3AP
1997-12-10Manufacturing (CMC) · Supplement 2AP
1996-08-27Manufacturing (CMC) · Supplement 1AP
1980-03-10OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →